Last reviewed · How we verify

NCT06310135

Filtered Eyewear to Prevent Light-induced Melatonin Suppression - Aim 1

Completed NA Last updated 5 August 2025
What this trial tests

NA trial testing Filtered Eyewear in Sleep Quality in 29 participants. Completed in 31 October 2024.

Timeline
1 May 2024
Primary endpoint
31 October 2024
31 October 2024

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposetreatment
Enrollment29
Start date1 May 2024
Primary completion31 October 2024
Estimated completion31 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Sleep Quality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the relative effectiveness of monocular and binocular light exposures, with and without selective blue-blocking filtering, on nocturnal melatonin suppression, subjective sleepiness, and visual performance of night shift workers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The Impact of a Blue-Blocking Filter Over One Eye on Health and Performance Outcomes and Its Implications for Night Workers.
    Figueiro MG, Bullough JD, Rizvydeen M, Plitnick B, et al · · 2026 · PMID 41353624 · DOI 10.1177/10998004251406550

Verify or expand the search:

Other recruiting trials for Sleep Quality

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06310135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing